Operates non-residential healthcare centers specifically for children. Provides day care services for medically and technologically dependent children. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 51.5× for every dollar of annual revenue.
No analyst target is on record for this company.
Over the last 2 years, sales grew about 586% a year on average.
Sales run at $881K a year. A small number, but proof the product has real buyers.
A loss of $118K against $881K in annual sales.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown, the price history.